UNISOUND AI Technology Co., Ltd. announced the commercial roll-out of its proprietary medical imaging multi-modal large model, U2-RadiMed. The platform integrates image interpretation, report generation, clinical reasoning, decision-making, and visual question answering in a single solution, supporting mixed inputs of chest X-rays, CT and MRI images together with text.

U2-RadiMed forms a six-pillar capability suite—report generation, lesion detection and localization, clinical reasoning, clinical decision-making, general medical visual Q&A, and advanced medical reasoning—enabling a complete workflow from image review to conclusion. In independent benchmarks, the model achieved an overall score of 55.47, topping competitors such as Gemini 3.1 and GPT-5.4. It also ranked first in four specialist sub-categories, posting a 37.58 score in lesion detection and localization, and led the MedBench 5.0 full-modality evaluation with 57.20.

On the application front, U2-RadiMed addresses traditional AI limitations in single-image analysis by handling multi-temporal image comparisons, disease-progression tracking, differential diagnosis, and automated report drafting. Deployed on UNISOUND’s MaaS platform “Token Hub”, the model offers multi-image input and a 40K-token context window, facilitating rapid integration into radiology and clinical workflows across medical institutions.

Management underscored that the launch extends UNISOUND’s product stack—from a general foundational LLM to the tri-medical professional LLM and now the dedicated medical imaging model—reinforcing the company’s leadership in medical AI. Ongoing efforts will focus on broadening large-model applications across healthcare to enhance clinical efficiency and create long-term value for shareholders.